Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme
Open accessThe DOI matches its Crossref record; 61 of the 64 references it cites were found in a registry or an index.
Abstract
Neuroinflammation and cyclooxygenase-2 (COX-2) upregulation are associated with the pathogenesis of degenerative brain diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), epilepsy, and a response to traumatic brain injury (TBI) or stroke. COX-2 is also induced in acute pain, depression, schizophrenia, various cancers, arthritis and in acute allograft rejection. Positron emission tomography (PET) imaging allows for the direct measurement of in vivo COX-2 upregulation and thereby enables disease staging, therapy evaluation and aid quantifying target occupancy of novel nonsteroidal anti-inflammatory drugs or NSAIDs. Thus far, no clinically useful radioligand is established for monitoring COX-2 induction in brain diseases due to the delay in identifying qualified COX-2-selective inhibitors entering the brain. This review examines radiolabeled COX-2 inhibitors reported in the past decade and identifies the most promising radioligands for development as clinically useful PET radioligands. Among the radioligands reported so far, the three tracers that show potential for clinical translation are, [11CTMI], [11C]MC1 and [18F]MTP. These radioligands demonstrated BBB permeablity and in vivo binding to constitutive COX-2 in the brain or induced COX-2 during neuroinflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 (a) MRI and summed (0–120 min) PET images of [11C]TMI in healthy baboon: (b) total volume of distribution (VTs) in baboon brain, baseline and blocking, estimated using a one-tissue compartment (1TC), Logan plot and likelihood estimation in graphical analysis (LEGA) methods. CIN: cingulate cortex; CER: cerebellum; FRT: frontal cortex; HIP: hippocampus; ORB: orbital cortex; THA: thalamus.](https://figures.cochat.ai/paper-figures/cd3e7c4c65354662a5a856375afcd71d/progress-in-pet-imaging-of-neuroinflammation-targeting-cox-2-enzyme-figure-2.jpg)
![Figure 3 Representative microPET images of [18F]MTP in PBS- and LPS-administered mice (a); TACs of [18F]MTP in PBS- (green) and LPS (red)-treated mice (b).](https://figures.cochat.ai/paper-figures/10112ee9e5ba45278195dd669ec94cc3/progress-in-pet-imaging-of-neuroinflammation-targeting-cox-2-enzyme-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies confirm that chronic unpredictable stress increases the uptake of PET radioligands targeting the COX-2 enzyme and cerebral PGE-2 concentrations in susceptible compared to resilient mice (160).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [160]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925 · cited 2×
“COX-1 and COX-2 show >60% homology between humans and rodents [2].”
BackgroundCyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989
Neuroinflammation: The Devil Is in the Details
DiSabato, D. J., Quan, N., & Godbout, J. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13607 · Cited by 1,640 · cited 1×
“The degree of neuroinflammation depends on the context, duration and course of the primary stimulus [33].”
BackgroundCyclooxygenase-2 (COX-2) in Inflammatory and Degenerative Brain Diseases
Minghetti, L. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.9.901 · Cited by 779
Encyclopedia of Clinical Neuropsychology
(2011) · Springer eBooks · doi:10.1007/978-0-387-79948-3 · Cited by 726
Cyclooxygenases: structural and functional insights
Rouzer, C. A., & Marnett, L. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800042-jlr200 · Cited by 688
Banks, W. A., Gray, A. M., Erickson, M. A., Salameh, T. S., Damodarasamy, M., Sheibani, N., Meabon, J. S., Wing, E. E., Morofuji, Y., Cook, D. G., et al. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0434-1 · Cited by 636
Structural and Functional Basis of Cyclooxygenase Inhibition
Blobaum, A. L., & Marnett, L. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0613166 · Cited by 550
Protective effects of NSAIDs on the development of Alzheimer disease
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008) · Neurology · doi:10.1212/01.wnl.0000311269.57716.63 · Cited by 535 · cited 1×
“COX-2 induction is also reported in psychiatric disorders such as major depressive disorders (MDD) and schizophrenia [22,23].”
BackgroundZhang, J., Ding, E. L., & Song, Y. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60015 · Cited by 332
COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease
Willoughby, D. A., Moore, A. R., & Colville-Nash, P. R. (2000) · The Lancet · doi:10.1016/s0140-6736(99)12031-2 · Cited by 298
Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
Crofford, L. J., Lipsky, P. E., Brooks, P., Abramson, S. B., Simon, L. S., & Van De Putte, L. B. A. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<4::aid-anr2>3.0.co;2-v · Cited by 296
Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals
Eliopoulos, A. G. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf478 · Cited by 284
Werry, E. L., Bright, F. M., Piguet, O., Ittner, L. M., Halliday, G. M., Hodges, J. R., Kiernan, M. C., Loy, C. T., Kril, J. J., & Kassiou, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133161 · Cited by 279
Chemokines and cytokines in neuroinflammation leading to neuropathic pain
Kiguchi, N., Kobayashi, Y., & Kishioka, S. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.10.007 · Cited by 262
Physiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidney
Nørregaard, R., Kwon, T.-H., & Frøkiær, J. (2015) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2015.10.004 · Cited by 221
Badger, A. M., Griswold, D. E., Kapadia, R. D., Blake, S. M., Swift, B. A., Hoffman, S. J., Stroup, G. B., Webb, E. F., Rieman, D. J., Gowen, M., et al. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<1::aid-anr1>3.0.co;2-6 · Cited by 213
An overview of the cannabinoid type 2 receptor system and its therapeutic potential
Bie, B., Wu, J., Foss, J. F., & Naguib, M. (2018) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000616 · Cited by 206
Ho, L., Purohit, D., Haroutunian, V., Luterman, J. D., Willis, F., Naslund, J., Buxbaum, J. D., Mohs, R. C., Aisen, P. S., & Pasinetti, G. M. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.487 · Cited by 198
Cyclooxygenase-2 in synaptic signaling
Yang, H., & Chen, C. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784480144 · Cited by 195 · cited 1×
“In the human brain, COX-2 is mainly expressed in the cerebral cortex, hippocampus, hypothalamus, midtemporal gyrus, substantia nigra, thalamus, caudate, cerebellum, and amygdala [19].”
BackgroundProstaglandins: Effects on blood pressure, renal blood flow, sodium and water excretion
Anderson, R. J., Berl, T., McDonald, K. M., & Schrier, R. W. (1976) · Kidney International · doi:10.1038/ki.1976.99 · Cited by 171
Neuroinflammation, COX-2, and ALS—a dual role?
Consilvio, C., Vincent, A. M., & Feldman, E. L. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2003.12.009 · Cited by 171
Central Nervous System Concentrations of Cyclooxygenase-2 Inhibitors in Humans
Dembo, G., Park, S. B., & Kharasch, E. D. (2005) · Anesthesiology · doi:10.1097/00000542-200502000-00026 · Cited by 147
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
Hernán, M. A., Logroscino, G., & Rodríguez, L. A. G. (2006) · Neurology · doi:10.1212/01.wnl.0000204446.82823.28 · Cited by 137
Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology
Hoozemans, J., Rozemuller, J., van Haastert, E., Veerhuis, R., & Eikelenboom, P. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784480171 · Cited by 137
Xiang, Z., Ho, L., Yemul, S., Zhao, Z., Pompl, P., Kelley, K., Dang, A., Qing, W., Teplow, D., & Pasinetti, G. M. (2002) · Gene Expression · doi:10.3727/000000002783992352 · Cited by 135
COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
Davies, N. M., & Jamali, F. (2004) · PubMed · Cited by 126
Prabhakaran, J., Underwood, M. D., Parsey, R. V., Arango, V., Majo, V. J., Simpson, N. R., Heertum, R. V., Mann, J. J., & Kumar, J. S. D. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.11.033 · Cited by 126
Self-citationMcCluskey, S. P., Plisson, C., Rabiner, E. A., & Howes, O. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04488-0 · Cited by 120
Adeno-Associated Viral Vectors in Neuroscience Research
Haggerty, D. L., Grecco, G. G., Reeves, K. C., & Atwood, B. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.012 · Cited by 118
Cyclooxygenase and Neuroinflammation in Parkinsons Disease Neurodegeneration
Bartels, A., & Leenders, K. (2010) · Current Neuropharmacology · doi:10.2174/157015910790909485 · Cited by 112
Xiang, Z., Ho, L., Valdellon, J., Borchelt, D., Kelley, K., Spielman, L., Aisen, P. S., & Pasinetti, G. M. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00282-2 · Cited by 111
COX-2 in Brain and Spinal Cord - Implications for Therapeutic Use.
Hoffmann, C. (2000) · Current Medicinal Chemistry · doi:10.2174/0929867003374282 · Cited by 110
A central role for P2X7 receptors in human microglia
Janks, L., Sharma, C. V. R., & Egan, T. M. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1353-8 · Cited by 110
Role of Cyclooxygenase-2 in Neuronal Cell Cycle Activity and Glutamate-Mediated Excitotoxicity
Mirjany, M., Ho, L., & Pasinetti, G. M. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.494 · Cited by 109
Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial1
Luo, C., He, M., & Bohlin, L. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00150.x · Cited by 83
Laube, M., Knieß, T., & Pietzsch, J. (2013) · Molecules · doi:10.3390/molecules18066311 · Cited by 80
TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases?
Largeau, B., Dupont, A.-C., Guilloteau, D., Ribeiro, M. J., & Arlicot, N. (2017) · Contrast Media & Molecular Imaging · doi:10.1155/2017/6592139 · Cited by 62
Imaging of Cyclooxygenase-2 (COX-2) Expression: Potential Use in Diagnosis and Drug Evaluation
de Vries, E. F. J. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778559650 · Cited by 59
Habeeb, A. G., Rao, P. P. N., & Knaus, E. E. (2000) · Drug Development Research · doi:10.1002/ddr.9 · Cited by 56
Shrestha, S., Kim, M.-J., Eldridge, M., Lehmann, M. L., Frankland, M., Liow, J.-S., Yu, Z.-X., Cortes-Salva, M., Telu, S., Henter, I. D., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01804-6 · Cited by 55
Immunohistochemical Expression of Cyclooxygenase-2 in Normal Kidneys
Adegboyega, P. A., & Ololade, O. (2004) · Applied immunohistochemistry & molecular morphology · doi:10.1097/00129039-200403000-00013 · Cited by 52
Synthesis of [11C]celecoxib: a potential PET probe for imaging COX‐2 expression
Prabhakaran, J., Majo, V. J., Simpson, N. R., Heertum, R. L. V., Mann, J. J., & Kumar, J. S. D. (2005) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.1002 · Cited by 52
Self-citationSelective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine
Praticò, D., & Dogné, J.-M. (2005) · Circulation · doi:10.1161/circulationaha.104.524231 · Cited by 50
Radiosynthesis of 1‐[11C] polyhomoallylic fatty acids
Channing, M. A., & Simpson, N. R. (1993) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2580330611 · Cited by 46
COX-2 expression and function in the hyperalgesic response to paw inflammation in mice
Jain, N., Ishikawa, T., Spigelman, I., & Herschman, H. R. (2008) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2008.08.001 · Cited by 37
Radiochemistry on electrodes: Synthesis of an 18F-labelled and in vivo stable COX-2 inhibitor
Lebedev, A. Y., Jiao, J., Lee, J. T., Yang, F., Allison, N., Herschman, H. R., & Sadeghi, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176606 · Cited by 34
In vivo evaluation of [11C]TMI, a COX-2 selective PET tracer, in baboons
Kumar, J. S. D., Zanderigo, F., Prabhakaran, J., Rubin‐Falcone, H., Parsey, R. V., & Mann, J. J. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.10.049 · Cited by 34
Self-citationKaur, J. P., Tietz, O., Bhardwaj, A., Marshall, A., Way, J., Wuest, M., & Wuest, F. R. (2015) · ChemMedChem · doi:10.1002/cmdc.201500287 · Cited by 32
Kumar, J. S. D., Bai, B., Zanderigo, F., DeLorenzo, C., Prabhakaran, J., Parsey, R. V., & Mann, J. J. (2018) · Molecules · doi:10.3390/molecules23081929 · Cited by 31
Self-citationAssessment of radioligands for PET imaging of cyclooxygenase-2 in an ischemic neuronal injury model
Ji, B., Kumata, K., Onoe, H., Kaneko, H., Zhang, M., Seki, C., Ono, M., Shukuri, M., Tokunaga, M., Minamihisamatsu, T., et al. (2013) · Brain Research · doi:10.1016/j.brainres.2013.08.026 · Cited by 29
Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach
Rodriguez‐Vieitez, E., & Nordberg, A. K. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7704-8_16 · Cited by 26
Roughead, E. E., Ramsay, E. N., Pratt, N. L., & Gilbert, A. L. (2008) · Drug Safety · doi:10.2165/00002018-200831110-00004 · Cited by 22
Selective cyclooxygenase-2 inhibitors
Auleley, G.-R., Deligne, J., Hantson, C., & Blum‐Boisgard, C. (2005) · La Presse Médicale · doi:10.1016/s0755-4982(05)84023-0 · Cited by 19
Yamamoto, Y., Toyohara, J., Ishiwata, K., Sano, K., Yamamoto, F., Mukai, T., & Maëda, M. (2011) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.59.938 · Cited by 17
Radiosynthesis and in vivo evaluation of [11C]MOV as a PET imaging agent for COX-2
Prabhakaran, J., Underwood, M. D., Zanderigo, F., Simpson, N. R., Cooper, A. R., Matthew, J., Rubin‐Falcone, H., Parsey, R. V., Mann, J. J., & Kumar, J. S. D. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.06.015 · Cited by 14
Self-citationRadiosynthesis and evaluation of [18F]FMTP, a COX-2 PET ligand
Kumar, J. S. D., Prabhakaran, J., Molotkov, A., Sattiraju, A., Kim, J., Doubrovin, M., Mann, J. J., & Mintz, A. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00124-z · Cited by 9
Self-citation[11C]arachidonic acid incorporation measurement in human brain: Optimization for clinical use
Zanderigo, F., Kang, Y., Kumar, D. J. S., Nikolopoulou, A., Mozley, P. D., Kothari, P. J., He, B., Schlyer, D. J., Rapoport, S. I., Oquendo, M. A., et al. (2017) · Synapse · doi:10.1002/syn.22018 · Cited by 8
Self-citationFDA Approves First Celecoxib Generics
Kuehn, B. M. (2014) · JAMA · doi:10.1001/jama.2014.7533 · Cited by 6
Selective cyclooxygenase-2 inhibition: biological and clinical effects.
Conti, F., Spinelli, F. R., Ossandon, A., & Valesini, G. (2000) · PubMed · Cited by 2
Research works printed but not linked: 2
- Pal, 2018, Incidence and Prevalence of Major Neurologic Disorders, Neurology, 43, 24
- Cortes, 2015, Synthesis of PET radioligands as potential probes for imaging COX-2 in neuroinflammation, J. Nucl. Med., 56, 1092
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
Arachidonic acid metabolism in health and disease
Zhang, Y., Liu, Y., Sun, J., Zhang, W., Guo, Z., & Ma, Q. (2023) · MedComm · doi:10.1002/mco2.363 · Cited by 295
The Interplay between Ferroptosis and Neuroinflammation in Central Neurological Disorders
Xu, Y., Jia, B., Li, J., Li, Q., & Luo, C. (2024) · Antioxidants · doi:10.3390/antiox13040395 · Cited by 113
Zhang, L., Li, M., Wang, W., Yu, W., Liu, H., Wang, K., Chang, M., Deng, C., Ji, Y., Shen, Y., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115186 · Cited by 79
Traumatic Brain Injury and Early Onset Dementia in Post 9-11 Veterans
Kennedy, E., Panahi, S., Stewart, I. J., Tate, D. F., Wilde, E. A., Kenney, K., Werner, J. K., Gill, J., Diaz-Arrastia, R. R., Amuan, M. E., et al. (2022) · Brain Injury · doi:10.1080/02699052.2022.2033846 · Cited by 45
Metadata
- Authors
- Prabhakaran, J., Molotkov, A., Mintz, A., & Mann, J. J.
- Affiliations
- Columbia University Irving Medical Center (US)
- Corresponding author
- Prabhakaran, Jaya
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-05-27
- Volume
- 26
- Issue
- 11
- Pages
- 3208
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8198977
- OpenAlex
- W3165497367
- Cited by
- 74
- References
- 64
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 15 · 2023: 22 · 2022: 12 · 2021: 2
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (R01AG070042)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- neuroinflammation, cyclooxygenase-2, PET radiotracer, COX-2 inhibitors, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, stroke, nonsteroidal anti-inflammatory drugs, target occupancy
- MeSH terms
- Celecoxib, Animals, Anti-Inflammatory Agents, Blood-Brain Barrier, Brain, Central Nervous System Diseases, Chemistry, Pharmaceutical, Female, Humans, Inflammation, Kinetics, Ligands, Magnetic Resonance Imaging, Male, Papio, Permeability, Positron-Emission Tomography, Mice, Rats, Cyclooxygenase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.